Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 18 - Number 8
Biography
Review Article
The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies
, 18(8): 720 - 736Avineesh Singh, Preeti Patel, Jageshwar, Vijay Kumar Patel, Deepak Kumar Jain, M. Kamal and Harish Rajak*
DOI: 10.2174/1568009617666170630124643
Review Article
Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
, 18(8): 737 - 748Leila Farahmand, Parnaz Merikhian, Neda Jalili, Behrad Darvishi and Keivan Majidzadeh-A*
DOI: 10.2174/1568009617666170623113520
Review Article
p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
, 18(8): 749 - 772Surendra Kumar Nayak*, Gopal L. Khatik, Rakesh Narang, Vikramdeep Monga and Harish Kumar Chopra
DOI: 10.2174/1568009617666170623111953
Review Article
Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
, 18(8): 773 - 791Dhaval Sanchala, Lokesh K. Bhatt* and Kedar S. Prabhavalkar
DOI: 10.2174/1568009617666170623123848
Review Article
Development of Drug Targeting and Delivery in Cervical Cancer
, 18(8): 792 - 806Urvashi Aggarwal, Amit Kumar Goyal and Goutam Rath*
DOI: 10.2174/1568009617666171009165105
Research Article
A High-throughput Quantitative Expression Analysis of Cancer-related Genes in Human HepG2 Cells in Response to Limonene, a Potential Anticancer Agent
, 18(8): 807 - 815Rand R. Hafidh*, Saba Z. Hussein, Mohammed Q. MalAllah, Ahmed S. Abdulamir and Fatimah Abu Bakar
DOI: 10.2174/1568009617666171114144236
Research Article
JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells
, 18(8): 816 - 828Ilaria Zanellato*, Donato Colangelo and Domenico Osella
DOI: 10.2174/1568009617666170623101722
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Advertisement
Webmaster Contact: info@benthamscience.net